{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:18:21Z","timestamp":1788290301418,"version":"build-2803163510"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>This review summarizes the emerging role of the fibrinolytic system in the pathogenesis of systemic sclerosis (SSc) and its potential as a source of novel therapeutic targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      Increasing evidence indicates that SSc is characterized by impaired fibrinolysis, largely driven by upregulation of plasminogen activator inhibitor-1 (PAI-1) and \u03b12-antiplasmin, which limits extracellular matrix degradation and promotes myofibroblast differentiation. A key pathogenic mechanism involves matrix metalloproteinase-12-mediated proteolytic cleavage of the urokinase-type plasminogen activator receptor (uPAR), which compromises angiogenesis and promotes endothelial-to-mesenchymal transition, thereby contributing to both vascular remodeling and fibrosis. Moreover, aberrant crosstalk between cleaved uPAR and N-formyl peptide receptors (FPRs) on fibroblasts induces excessive reactive oxygen species generation and sustained fibroblast proliferation. Clinically, circulating soluble uPAR and\n                      <jats:italic toggle=\"yes\">PLAUR<\/jats:italic>\n                      gene polymorphisms have emerged as candidate biomarkers of severe microvascular dysfunction and internal organ involvement. From a therapeutic perspective, several innovative strategies, including uPAR-targeting peptides, PAI-1 inhibitors, and molecules disrupting uPAR-FPR interaction, have shown encouraging antifibrotic efficacy in preclinical models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The fibrinolytic system has emerged as a central molecular hub linking SSc microvascular dysfunction, immune dysregulation, and fibrosis. Thus, restoring fibrinolytic homeostasis may offer a promising strategy to simultaneously improve angiogenesis, reduce fibrosis, and slow disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001186","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:03:07Z","timestamp":1787144587000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Beyond fibrinolysis: the multifaceted role of the fibrinolytic system in systemic sclerosis"],"prefix":"10.1097","author":[{"given":"Irene","family":"Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Manetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"R1-20260901","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41584-025-01349-z","article-title":"Mechanisms of fibrotic tissue remodelling: insights from systemic sclerosis","volume":"22","author":"Distler","year":"2026","journal-title":"Nat Rev Rheumatol"},{"key":"R2-20260901","doi-asserted-by":"crossref","first-page":"e895","DOI":"10.1016\/S2665-9913(25)00251-6","article-title":"Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosis","volume":"7","author":"Pauling","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R3-20260901","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00011-025-02126-0","article-title":"Systemic sclerosis, main culprits and involved signaling pathways","volume":"74","author":"Sadatpour","year":"2025","journal-title":"Inflamm Res"},{"key":"R4-20260901","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/BOR.0000000000001126","article-title":"Decoding vascular dysfunction in systemic sclerosis: from endothelial damage to clinical implications","volume":"37","author":"Massay","year":"2025","journal-title":"Curr Opin Rheumatol"},{"key":"R5-20260901","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/ijms20030619","article-title":"The role of fibrinolytic regulators in vascular dysfunction of systemic sclerosis","volume":"20","author":"Kanno","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R6-20260901","doi-asserted-by":"crossref","first-page":"9596","DOI":"10.3390\/ijms26199596","article-title":"Role of growth factors in the pathogenesis of systemic-sclerosis-associated fibrosis","volume":"26","author":"Mendoza","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R7-20260901","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/ijms24021796","article-title":"The uPA\/uPAR system orchestrates the inflammatory response, vascular homeostasis, and immune system in fibrosis progression","volume":"24","author":"Kanno","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R8-20260901","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/path.2048","article-title":"Systemic sclerosis fibroblasts inhibit in vitro angiogenesis by MMP-12-dependent cleavage of the endothelial cell urokinase receptor","volume":"210","author":"Serrat\u00ec","year":"2006","journal-title":"J Pathol"},{"key":"R9-20260901","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2011-200837","article-title":"Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage","volume":"71","author":"Manetti","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R10-20260901","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1002\/art.22263","article-title":"Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, \u03b22 integrin\u2013mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells","volume":"54","author":"Margheri","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R11-20260901","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1093\/rheumatology\/keab022","article-title":"Glycolysis-derived acidic microenvironment as a driver of endothelial dysfunction in systemic sclerosis","volume":"60","author":"Andreucci","year":"2021","journal-title":"Rheumatology"},{"key":"R12-20260901","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/life11070610","article-title":"New insights into profibrotic myofibroblast formation in systemic sclerosis: when the vascular wall becomes the enemy","volume":"11","author":"Romano","year":"2021","journal-title":"Life"},{"key":"R13-20260901","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R14-20260901","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/life12030396","article-title":"\u03b12-Antiplasmin as a potential therapeutic target for systemic sclerosis","volume":"12","author":"Kanno","year":"2022","journal-title":"Life"},{"key":"R15-20260901","doi-asserted-by":"crossref","first-page":"100906","DOI":"10.1016\/j.bj.2025.100906","article-title":"Plasminogen activator Inhibitor-1 in systemic sclerosis: a nexus of fibrosis, vasculopathy, and senescence","volume":"49","author":"Takahashi","year":"2026","journal-title":"Biomed J"},{"key":"R16-20260901","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13287-026-04923-8","article-title":"uPAR deficiency triggers TGF\u03b21-mediated fibrotic remodeling in a cardiac perivascular-like microenvironment","volume":"17","author":"Goltseva","year":"2026","journal-title":"Stem Cell Res Ther"},{"key":"R17-20260901","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1091\/mbc.e06-10-0912","article-title":"Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation","volume":"18","author":"Bernstein","year":"2007","journal-title":"Mol Biol Cell"},{"key":"R18-20260901","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.4049\/jimmunol.1402819","article-title":"Upregulation of the N-formyl peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts","volume":"194","author":"Rossi","year":"2015","journal-title":"J Immunol"},{"key":"R19-20260901","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.3390\/ijms25063156","article-title":"The crosstalk between N-formyl peptide receptors and uPAR in systemic sclerosis: molecular mechanisms, pathogenetic role and therapeutic opportunities","volume":"25","author":"Napolitano","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R20-20260901","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3389\/fimmu.2018.00574","article-title":"N-Formyl peptide receptors induce radical oxygen production in fibroblasts derived from systemic sclerosis by interacting with a cleaved form of urokinase receptor","volume":"9","author":"Napolitano","year":"2018","journal-title":"Front Immunol"},{"key":"R21-20260901","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/039463201002300325","article-title":"The plasminogen activator system in fibroblasts from systemic sclerosis","volume":"23","author":"Postiglione","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R22-20260901","doi-asserted-by":"crossref","first-page":"845956","DOI":"10.3389\/fimmu.2022.845956","article-title":"The uPA system differentially alters fibroblast fate and profibrotic ability in skin fibrosis","volume":"13","author":"Zou","year":"2022","journal-title":"Front Immunol"},{"key":"R23-20260901","doi-asserted-by":"crossref","first-page":"e181427","DOI":"10.1172\/jci.insight.181427","article-title":"Adipocyte-specific deletion of sine oculis homeobox homolog 1 inhibits lipolysis and reduces skin fibrosis","volume":"11","author":"Wareing","year":"2026","journal-title":"JCI Insight"},{"key":"R24-20260901","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2353\/ajpath.2010.090150","article-title":"\u03b12-Antiplasmin is associated with the progression of fibrosis","volume":"176","author":"Kanno","year":"2010","journal-title":"Am J Pathol"},{"key":"R25-20260901","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jid.2015.12.028","article-title":"The antifibrotic effect of \u03b12AP neutralization in systemic sclerosis dermal fibroblasts and mouse models of systemic sclerosis","volume":"136","author":"Kanno","year":"2016","journal-title":"J Invest Dermatol"},{"key":"R26-20260901","doi-asserted-by":"crossref","first-page":"21210","DOI":"10.1038\/s41598-021-99520-5","article-title":"TGF-( regulation of the uPA\/uPAR axis modulates mesothelial-mesenchymal transition (MesoMT)","volume":"11","author":"Logan","year":"2021","journal-title":"Sci Rep"},{"key":"R27-20260901","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.biocel.2018.02.016","article-title":"The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis","volume":"97","author":"Schuliga","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"R28-20260901","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/ijms24021382","article-title":"Urokinase system in pathogenesis of pulmonary fibrosis: a hidden threat of COVID-19","volume":"24","author":"Shmakova","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R29-20260901","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2013-203706","article-title":"Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?","volume":"73","author":"Manetti","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R30-20260901","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1038\/jid.2008.157","article-title":"The absence of uPAR is associated with the progression of dermal fibrosis","volume":"128","author":"Kanno","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R31-20260901","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/annrheumdis-2015-207803","article-title":"Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice","volume":"75","author":"Manetti","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R32-20260901","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10517-022-05480-9","article-title":"Deficiency of urokinase-type plasminogen activator receptor is associated with the development of perivascular fibrosis in mouse heart","volume":"173","author":"Dergilev","year":"2022","journal-title":"Bull Exp Biol Med"},{"key":"R33-20260901","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/cbin.12222","article-title":"Mesenchymal stem\/stromal cells alleviate early-stage pulmonary fibrosis in a uPAR-dependent manner","volume":"48","author":"Efimenko","year":"2024","journal-title":"Cell Biol Int"},{"key":"R34-20260901","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2249.2005.02718.x","article-title":"Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma","volume":"139","author":"Matsushita","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"R35-20260901","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1161\/ATVBAHA.117.309383","article-title":"PAI-1 (Plasminogen Activator Inhibitor-1) expression renders alternatively activated human macrophages proteolytically quiescent","volume":"37","author":"Hohensinner","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R36-20260901","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1515\/cclm-2015-0079","article-title":"Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis","volume":"53","author":"Leg\u00e1ny","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"R37-20260901","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/art.30101","article-title":"A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis","volume":"63","author":"Manetti","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R38-20260901","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1697785","article-title":"Serum profiling of uPA, PAI-1, and suPAR in systemic sclerosis: a preliminary study on analytical aspects and associations with microvascular and fibrotic manifestations","volume":"16","author":"Napolitano","year":"2025","journal-title":"Front Immunol"},{"key":"R39-20260901","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3390\/life14091056","article-title":"Impact of plasminogen activator inhibitor-1 serum levels and the -675\u200a4G\/5G variant in the SERPINE1 gene on systemic sclerosis in a Mexican population","volume":"14","author":"Lomel\u00ed-Nieto","year":"2024","journal-title":"Life"},{"key":"R40-20260901","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/sarh.2002.50011","article-title":"Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis","volume":"32","author":"Cerinic","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"R41-20260901","doi-asserted-by":"crossref","first-page":"e144935","DOI":"10.1172\/jci.insight.144935","article-title":"E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects","volume":"6","author":"Sharma","year":"2021","journal-title":"JCI Insight"},{"key":"R42-20260901","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1055\/s-0039-1697953","article-title":"Urokinase plasminogen activator overexpression reverses established lung fibrosis","volume":"119","author":"Horowitz","year":"2019","journal-title":"Thromb Haemost"},{"key":"R43-20260901","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/jgm.1206","article-title":"Transplantation of urokinase-type plasminogen activator gene-modified bone marrow-derived liver stem cells reduces liver fibrosis in rats","volume":"10","author":"Sun","year":"2008","journal-title":"J Gene Med"},{"key":"R44-20260901","doi-asserted-by":"crossref","first-page":"e195005","DOI":"10.1172\/jci.insight.195005","article-title":"A potent inhibitor of PAI-1, MDI-2517, mitigates disease severity in a preclinical systemic sclerosis model","volume":"11","author":"Su","year":"2026","journal-title":"JCI Insight"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:00:21Z","timestamp":1788289221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":44,"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001186","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}